- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07763145
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy
Effect of Citicoline on Neurological Severity Score and Cerebral Doppler Resistive Index in Neonatal Hypoxic Ischemic Encephalopathy: A Randomized Control Trial
Studie Overzicht
Toestand
Interventie / Behandeling
Gedetailleerde beschrijving
Hypoxic-ischemic encephalopathy (HIE) is a leading cause of neonatal brain injury worldwide. In the developed world, the incidence is estimated at up to 8 per 1,000 live births, while in developing countries, estimates are as high as 26 per 1,000 live births. Approximately 20-30% of infants with HIE die in the neonatal period, and 33-50% of survivors are left with permanent neurodevelopmental abnormalities.1 HIE can be classified into mild (Stage I), moderate (Stage II), and severe (Stage III) based on the Sarnat and Sarnat staging system(Table 1), with stage II and III being associated with the highest morbidity and mortality.
Therapeutic hypothermia remains the standard therapy for HIE. However, its availability, high costs, need for specialized equipment and monitoring limit its use in developing countries like Pakistan, therefore alternative neuroprotective agents are used however there is still no consensus regarding which agent is the most effective. Citicoline (cytidine diphosphate choline) has demonstrated several neuroprotective mechanisms. It helps preserve neuronal membrane integrity by maintaining phospholipids while decreasing phospholipase A2 activity and oxidative damage.2 It also enhances phosphatidylcholine synthesis and promotes glutathione production, thereby decreasing free-radical-mediated neuronal injury. Experimental studies further suggest neuroprotective roles of citicoline as it modulates excitotoxicity by decreasing glutamate levels.3,4 These combined effects may contribute to improved neuronal survival and recovery after hypoxic-ischemic insults. Long term effects have been studied however no study evaluates short term improvement from therapy.
Resistive Index is a parameter assessed on cranial doppler ultrasonography, it is difference between peak systolic and end diastolic pressures in the anterior cerebral arteries, normal value is 0.68-0.72 5it demonstrates cerebral blood flow changes due to hypoxia, lower values have been associated with worse neurological outcome.5 RI has been studied in comparison to MRI and also its changes pre and post therapeutic hypothermia, and has been found to be useful tool6,7. American Academy of Neurology and Practice Committee of the Child Neurology Society recommends RI and end diastolic flow velocity (EDFV) in the anterior cerebral artery to assess cerebral perfusion and early prediction of outcome.8 This study is therefore designed to assess the effect of citicoline on cerebral resistive index and neurological improvement using Sarnat-Sarnat scoring after 3 days of treatment in neonates with hypoxic-ischemic encephalopathy. The findings may contribute to establishing evidence for adjunctive therapeutic strategies aimed at reducing neurological morbidity in affected neonates. Despite its clinical use in some centers, there is limited published evidence regarding the efficacy of citicoline in neonates with HIE.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Romisa Rehman, FCPS, MRCPCH
- Telefoonnummer: 00923219059305
- E-mail: measa_awan@hotmail.com
Studie Locaties
-
-
KPK
-
Peshawar, KPK, Pakistan, 25000
- Hayatabad Medical Complex
-
Contact:
- Romisa Rehman, FCPS, MRCPCH
- Telefoonnummer: 00923219059305
- E-mail: measa_awan@hotmail.com
-
Hoofdonderzoeker:
- Romisa Rehman, MBBS, FCPS, MRCPCH
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
Accepteert gezonde vrijwilligers
Beschrijving
Inclusion Criteria:
- All inborn neonates diagnosed with APGAR score (Table 2) less then 8/10 at 5 min of life presenting to the emergency room within the first day of life.
- Outborn babies admitted in the last 24 hours with history or clinical features of perinatal asphyxia.
EXCLUSION CRITERIA :
- Neonates who have received therapeutic hypothermia
- Neonates with congenital, developmental or chromosomal malformations
- Significant antenatal risk factors leading to early-onset sepsis\DIC or CNS depression unrelated to asphyxia
- Preterm neonates <35 weeks
- No consent could be obtained
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Verviervoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Intervention Group
This will receive medicine citicoline with standard care
|
This group will receive drug and standard care
|
|
Placebo-vergelijker: Control group
Only receive standard care
|
This group will receive only standard care
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Sarnat and Sarnat scoring
Tijdsspanne: enrollment to 72 hours
|
enrollment to 72 hours
|
|
Cerebral Resistive Index
Tijdsspanne: Enrollment to 72 hours
|
Enrollment to 72 hours
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Romisa Rehman, Hyatabad Medical Complex
Publicaties en nuttige links
Algemene publicaties
- Edwards AD, Brocklehurst P, Gunn AJ, Halliday H, Juszczak E, Levene M, Strohm B, Thoresen M, Whitelaw A, Azzopardi D. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ. 2010 Feb 9;340:c363. doi: 10.1136/bmj.c363.
- Salamah A, El Amrousy D, Elsheikh M, Mehrez M. Citicoline in hypoxic ischemic encephalopathy in neonates: a randomized controlled trial. Ital J Pediatr. 2023 May 12;49(1):55. doi: 10.1186/s13052-023-01452-5.
- Gerner GJ, Burton VJ, Poretti A, Bosemani T, Cristofalo E, Tekes A, Seyfert D, Parkinson C, Leppert M, Allen M, Huisman TA, Northington FJ, Johnston MV. Transfontanellar duplex brain ultrasonography resistive indices as a prognostic tool in neonatal hypoxic-ischemic encephalopathy before and after treatment with therapeutic hypothermia. J Perinatol. 2016 Mar;36(3):202-6. doi: 10.1038/jp.2015.169. Epub 2015 Nov 26.
- Snyder EJ, Perin J, Chavez-Valdez R, Northington FJ, Lee JK, Tekes A. Head Ultrasound Resistive Indices Are Associated With Brain Injury on Diffusion Tensor Imaging Magnetic Resonance Imaging in Neonates With Hypoxic-Ischemic Encephalopathy. J Comput Assist Tomogr. 2020 Sep/Oct;44(5):687-691. doi: 10.1097/RCT.0000000000001069.
- Hurtado O, Moro MA, Cardenas A, Sanchez V, Fernandez-Tome P, Leza JC, Lorenzo P, Secades JJ, Lozano R, Davalos A, Castillo J, Lizasoain I. Neuroprotection afforded by prior citicoline administration in experimental brain ischemia: effects on glutamate transport. Neurobiol Dis. 2005 Mar;18(2):336-45. doi: 10.1016/j.nbd.2004.10.006.
- Adibhatla RM, Hatcher JF, Dempsey RJ. Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem. 2002 Jan;80(1):12-23. doi: 10.1046/j.0022-3042.2001.00697.x.
- Cohen SS, Sprecher AJ, Acharya KK. Hypoxic-ischemic encephalopathy. In: Kliegman RM, St. Geme JW, Blum NJ, Tasker RC, Wilson KM, Schuh AM, Mack CL, editors. Nelson Textbook of Pediatrics. 22nd ed. Vol 1. Philadelphia: Elsevier; 2024. p. 1062.
Studie record data
Bestudeer belangrijke data
Studie start (Geschat)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Cerebrovasculaire aandoeningen
- Hersenziekten
- Ziekten van het centrale zenuwstelsel
- Ziekten van het zenuwstelsel
- Vaatziekten
- Hart-en vaatziekten
- Ischemie van de hersenen
- Tekenen en symptomen, ademhaling
- Hypoxie, hersenen
- Hypoxie
- Pathologische aandoeningen, tekenen en symptomen
- Tekenen en symptomen
- Hypoxie-Ischemie, Hersenen
- Organische chemicaliën
- Heterocyclische verbindingen, 1-ring
- Heterocyclische verbindingen
- Nucleïnezuren, nucleotiden en nucleosiden
- Amines
- Pyrimidines
- Quaternaire ammoniumverbindingen
- Oniumverbindingen
- Trimethyl ammoniumverbindingen
- Ribonucleotiden
- Nucleotiden
- Choline
- Cytidinedifosfaat
- Cytosine -nucleotiden
- Pyrimidine -nucleotiden
- Cytidine Difosfaat Choline
Andere studie-ID-nummers
- ASRD 411
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .